A study found that patients undergoing elective total hip arthroplasty (THA) have a slightly improved survival rate compared to the general population. After ten years, higher survival rates were observed among THA patients, particularly those with primary osteoarthritis.
The CONCORD-3 study reveals global improvement in cancer survival, with some countries experiencing significant gains, while others lag behind. However, disparities in childhood cancers and incomplete data in Africa limit the accuracy of these findings.
Survival rates for in-hospital cardiac arrests have improved over the past 15 years, with a significant increase in both on-hours and off-hours groups. However, patients who experience cardiac arrest during nights or weekends continue to face lower survival rates compared to those who arrest during daytime hours.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
Patients with glioblastoma who received TTFields therapy plus chemotherapy had better overall survival and progression-free survival compared to those receiving chemotherapy alone. The study showed significant improvement in treatment outcomes for this aggressive brain tumor.
A new study found that inherited variation in the ADAMTSL1 gene is associated with a poorer survival rate in early-onset breast cancer patients. The research, published in Nature Communications, suggests that this genetic factor may be used to improve prognostic models and inform treatment decisions.
Large racial disparities were found in the survival of patients with ovarian, colon, and breast cancers in the United States. Black women had consistently worse survival compared to white women, despite similar stage distributions. The five-year net survival for black women was lower than for white women in all three types of cancer.
A subset analysis of the FLAURA trial found that osimertinib improved progression-free survival by 16.5 months compared to 11.0 months with standard therapy in Asian patients with EGFR-mutated non-small-cell lung cancer, resulting in a hazard ratio of 0.54.
A new study published in Gastroenterology found that health insurance coverage differences account for nearly half of the black-white survival disparity in colorectal cancer patients. The study analyzed data from 199,098 CRC patients aged 18-64 and found a significant impact of insurance status on treatment outcomes.
Researchers identified four genes - KRAS, CDKN2A, SMAD4, and TP53 - that influence pancreatic cancer survival. Patients with three or four altered genes had poorer disease-free and overall survival rates compared to those with single or dual alterations.
Researchers at Ohio State University Wexner Medical Center have discovered a DNA-level biomarker that can predict overall survival for patients with anaplastic astrocytoma, a rare form of brain cancer. The study found that MGMT promoter methylation status is significantly associated with overall survival outcomes.
A phase III trial demonstrates a 32 percent overall survival rate at five years, setting a new benchmark for patients with inoperable stage III NSCLC. The trial also confirms that using a higher radiation dose is not beneficial and can lead to detrimental outcomes.
Researchers found that children with Medicaid and private insurance had similar survival rates, but those without insurance were at a higher risk of death. The study suggests that Medicaid is comparable to private insurance for kids with cancer.
The COMBI-AD trial found that combination dabrafenib and trametinib therapy doubled relapse-free survival in stage III BRAF-mutant melanoma patients. The treatment was also shown to improve overall survival, distant metastases-free survival, and freedom from relapse.
The phase III RANGE trial showed that ramucirumab plus docetaxel significantly prolonged investigator-assessed progression-free survival compared to placebo plus docetaxel. The treatment also nearly doubled the objective response rate in patients with platinum-refractory advanced or metastatic urothelial cancer.
A phase III clinical trial found that osimertinib improves progression-free survival and median duration of response by 50-100% compared to standard first line therapy for patients with EGFR mutated non-small-cell lung cancer. The benefit was consistent across all subgroups, including those with and without brain metastases.
A recent study published in BMC Ecology found that grey mouse lemurs with high hair cortisol levels had a lower chance of survival. The researchers discovered that low cortisol levels were associated with a 13.9% higher chance of survival compared to those with high levels.
A study published in JAMA Cardiology found that out-of-hospital cardiac arrest treatment and survival rates differ by racial neighborhood composition. Neighborhoods with higher percentages of black residents had lower bystander CPR and defibrillator use, as well as lower survival rates compared to predominantly white neighborhoods.
Researchers have developed and validated a nomogram that can predict overall survival and progression-free survival for patients with oropharyngeal squamous cell carcinoma treated with radiation-based therapy. The nomograms were derived from clinical trials NRG Oncology/RTOG 0129 and 0522.
A recent study found improved survival rates among premature babies, with increased rates of survival without neuromotor and sensory disabilities at 2 years of age. However, a significant risk of developmental delay remains for children born between 24-34 weeks' gestation, with language development delays being the most common concern.
Researchers found that patients with deeper tumor shrinkage due to targeted treatment had better progression-free survival and overall survival rates. The study suggests that initial response could be an early indicator of a drug's effectiveness, influencing both clinical trials and treatment goals.
Survival rates for black and white patients with in-hospital cardiac arrest have improved over time, with black patients experiencing greater gains.
Researchers found that SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HPV-negative head and neck squamous cell carcinoma (HNSCC) patients. The study suggests that targeting pro-survival pathways may be a novel strategy for overcoming cetuximab resistance.
A new study links declining steelhead trout populations to poor survival rates of juvenile fish in the ocean. Ocean survival rates have declined by 77% in some areas, contributing to low adult abundance and impacting conservation efforts.
New research from the University of Pennsylvania School of Medicine finds that lenvatinib improves overall survival rates in older thyroid cancer patients who are resistant to standard radioiodine treatment. The drug is well-tolerated and has a significant impact on patient outcomes.
A study published in JAMA found that integrating electronic patient-reported outcomes into routine care led to a significant increase in survival among patients with metastatic cancer. The trial showed a median survival difference of 5 months between the electronic patient-reported symptom monitoring group and usual care.
A study published in JAMA found that using a combination of docetaxel and selumetinib did not improve progression-free or overall survival for patients with KRAS-mutant non-small cell lung cancer. The treatment had more frequent grade 3 or higher adverse events compared to the placebo group.
Researchers suggest that radiotherapy could have a role in extending the lives of patients with early-stage pancreatic cancer. Studies show that higher doses of radiation are associated with longer survival times. The study analyzed data from over 500 patients and found that those who received higher doses lived significantly longer.
Children and adolescents have a higher risk of dying from second cancers compared to older adults. The study found that survival rates are significantly lower for second cancers in young patients, particularly those under age 40.
Despite narrowing global inequalities in childhood leukemia survival, persistent disparities remain, with five-year survival rates varying widely between countries. The study highlights the need for improved access to efficient treatment and care for children with leukemia, particularly in low- and middle-income countries.
Researchers found similar disease-free survival and overall survival outcomes between laparoscopic and abdominal hysterectomies for stage I endometrial cancer. The study suggests the use of laparoscopic hysterectomy as a viable alternative to traditional abdominal surgery.
A study published in Annals of Internal Medicine found that Canadians with cystic fibrosis have a significant survival advantage over American patients, with a median age of survival of 50.9 years compared to 40.6 years in the US. The difference is attributed to better healthcare coverage and nutrition in Canada.
A new study reports improved kidney transplant success rates in children and infants over the past 53 years. The study found that young children now experience better long-term transplant success than adults, with almost 100 percent patient survival rate.
A nationwide study published in JACS found that critically ill children can now undergo liver transplantation and achieve similar survival benefits as stable children. Survival rates have improved significantly since pediatric critical care was recognized as a specialty area of medicine, with one-year survival increasing from 66% to 92%.
A new study published in Family Practice found that heart failure survival rates have not improved since 1998. The research team analyzed medical records from over 54,000 patients with heart failure and found varying survival rates based on age, gender, health conditions, and blood pressure.
A Phase IB/II study found that combining nivolumab with azacitidine improved response rates (34%) and overall survival (9.3 months) in patients with acute myeloid leukemia, compared to a historic response rate of 12-15% with azacitidine alone.
A recent study published in JAMA Pediatrics found that receiving cardiopulmonary resuscitation (CPR) from a bystander improved overall and neurologically favorable survival for children with out-of-hospital cardiac arrest. The study analyzed data from over 3,900 cases and showed that conventional CPR provided better outcomes than compr...
Higher vitamin D levels in blood are associated with better overall survival in breast cancer patients, according to a new study published in JAMA Oncology. The research found stronger associations between higher vitamin D levels and improved survival in premenopausal women.
A new study raises concerns about the effectiveness of expensive new cancer drugs in improving survival rates, citing limitations in clinical trials and high costs. Experts call for stricter approval criteria and improved patient consent processes to ensure fair and equitable treatment.
Researchers found that tailored dose-dense chemotherapy did not improve 5-year breast cancer recurrence-free survival, overall survival, or distant disease-free survival compared to standard chemotherapy. However, the tailored group experienced more nonhematologic toxic effects.
Researchers developed a new tool called SPIN-Score to predict survival after gunshot wounds, using pupil response and motor tests as key predictors. The tool accurately predicted survival rates with an excellent accuracy of 96%, offering valuable insights for doctors and families making life-or-death decisions.
Nintedanib significantly improves median progression-free survival compared to placebo, with disease control improved by 26% compared to 11% in the placebo group. However, overall survival did not differ between the two groups.
In the ASCEND-5 study, ceritinib significantly improved progression-free survival compared to chemotherapy in patients with non-small-cell lung cancer harbouring an ALK rearrangement. The primary endpoint was a median progression-free survival of 5.4 months with ceritinib versus 1.6 months with chemotherapy.
The CheckMate 026 trial found that nivolumab did not improve progression-free survival over chemotherapy in patients with PD-L1 positive tumours. However, combination immunotherapies are being investigated to potentially increase the proportion of patients who benefit from treatment.
The ASCEND-5 study showed ceritinib significantly improved progression-free survival compared to chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement. Ceritinib also increased overall response rate, but did not improve overall survival.
A phase III trial found ipilimumab as adjuvant therapy significantly improved overall survival in patients with high-risk stage III melanoma, reducing relative risk of death by 28% at 5.3 years median follow-up.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
A study published in JAMA compared five-year survival rates after endosonography and mediastinoscopy for mediastinal nodal staging of lung cancer. The endosonographic strategy was found to be more sensitive for diagnosing mediastinal nodal metastases.
Researchers found that overweight patients with metastatic kidney cancer had significantly longer survival and decreased risk of death compared to normal-weight counterparts. FASN gene expression was also found to be decreased in obese patients, which could explain their better treatment outcomes.
Mesenchymal stem cells exhibit significant cell-to-cell variation in their capacity to survive upon implantation. The Tulane professor's three-year project aims to gain insight into the molecular mechanisms underlying this variation, with the goal of improving survival rates and advancing regenerative therapies.
A population-based study found that air pollution may shorten the survival of patients with lung cancer, especially those with early stage disease. The study tracked over 352,000 people with lung cancer and found that higher exposure to pollutants like nitrogen dioxide and particulate matter was associated with shorter survival times.
According to a study published in JAMA, children with trisomy 13 and 18 showed significant improvement in survival rates after undergoing surgical interventions. The study found that one-year survival for these children was around 20-30%, with some even surviving up to 10 years.
Scientists have identified good bacteria as vital to coral health, enabling corals to recover from bleaching caused by rising temperatures. The study highlights the importance of understanding bacterial communities on corals to ensure long-term survival.
The extent of resection in glioblastoma patients was found to be associated with improved overall and progression-free survival. Glioblastoma multiforme (GBM) patients who underwent gross total resection (GTR) showed a significant increase in one-year and two-year survival rates compared to those with subtotal resection or biopsy.
Researchers at University of California - Davis Health found that patients with late-stage lung cancer who undergo surgery have better survival rates than those who don't. However, only 11% of these patients receive surgery, highlighting a need for improved access to care.
According to a new study published in The Lancet Oncology, teenagers and young adults have lower chances of surviving certain cancers compared to children. Despite improvements in overall childhood cancer survival rates, adolescents and young adults still tend to die earlier from blood cancers like leukaemias and non-Hodgkin's lymphoma.
Researchers found that 5-year survival for older lung cancer patients is favorable, with median survival at 6.7 years, and long-term patient outcomes including reduced hospital readmission rates and reinterventions.
A study published in JAMA found that pembrolizumab, an antibody against PD-1, was associated with a 33% objective response rate and 23-month median overall survival in patients with advanced melanoma. The treatment also showed improved progression-free survival rates of 35% at 12 months and 52% at 12 months
Scientists have mapped thousands of genetic mutations in yeast to understand their impact on cell survival. The study found that different combinations of mutations can influence survival and revealed a new technique for predicting the shapes of molecules encoded in our genes.
Patients with grade 2 glioma who received combined chemotherapy and radiation therapy experienced longer progression-free survival and overall survival compared to those who received radiation therapy alone. The study's findings suggest that initial therapy of RT followed by PCV is necessary to achieve longer survival.